B Lymphocyte News and Research

RSS

FADD protein discovery can lead to better cancer and autoimmune disease drugs

Reporting in Nature, scientists from Thomas Jefferson University have determined that a single protein called FADD controls multiple cell death pathways, a discovery that could lead to better, more targeted autoimmune disease and cancer drugs.

3 Mar 2011

IDF commends Illinois advisory committee for unanimous vote to recommend SCID Newborn Screening

The Illinois Genetic and Metabolic Diseases Advisory Committee voted unanimously to recommend that the Department of Health screen all newborns for Severe Combined Immune Deficiency (SCID) - commonly known as bubble boy disease.

9 Feb 2011

Researchers discover 'common set of dysregulated miRNAs in murine lupus models'

Potentially impacting future diagnosis and treatment of lupus, an immune illness affecting more than 5 million people worldwide, researchers at the Virginia-Maryland Regional College of Veterinary Medicine at Virginia Tech have likely uncovered where the breakdown in the body's lymphocyte molecular regulatory machinery is occurring.

1 Feb 2011

Analysis of medical database reveals new diagnostic markers for allergic disorders

Researchers at the University of Gothenburg, Sweden, have developed new methods for analysing medical databases that can be used to identify diagnostic markers more quickly and to personalise medication for allergic disorders. They could also reduce the need for animal trials in clinical studies.

12 Jan 2011

Genzyme provides information on peak sale of alemtuzumab for multiple sclerosis

Genzyme Corporation today provided an extensive briefing on the market potential of alemtuzumab for multiple sclerosis at an event for investors and analysts in New York.

21 Dec 2010

Preclinical study results for Syk, JAK inhibitor program presented at ASH 2010

Portola Pharmaceuticals, Inc. today announced the presentation of preclinical study results for its novel Syk and JAK inhibitor program at the American Society of Hematology's 52nd Annual Meeting and Exposition. Portola's novel Syk and JAK inhibitors are in development to treat chronic inflammatory diseases, including rheumatoid arthritis, and certain cancers, including non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

6 Dec 2010

Alexion Pharmaceuticals reports interim results from phase 1 trial on samalizumab antibody

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced the presentation of interim results from the first Phase I/II trial of samalizumab, the company's investigational, first-in-class humanized monoclonal antibody.

6 Dec 2010

Wake Forest University to begin clinical trial for low-grade gliomas

For patients with low-grade gliomas, or slow growing brain tumors, a shot in the arm might soon lead to a new treatment therapy. A groundbreaking, first in humans vaccine will be tested in an early phase clinical trial that will soon begin at Wake Forest University Baptist Medical Center. Eighteen patients will be the first in the world to receive it.

2 Dec 2010

Asbestos awareness important to prevent related cancer: Experts

Experts from Perth speculate Western Australia is yet to see the peak of asbestos-induced cancer, with renovators still failing to take proper precautions. According to director of the National Centre for Asbestos Related Diseases, Bruce Robinson, the next and third wave of mesothelioma patients would come out of those putting themselves and others at risk while taking on DIY home renovation projects.

22 Nov 2010

Myrexis presents key preclinical findings of MPI-0485520 at ACR/ARHP meeting

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today presented key preclinical findings of the Company's novel oral anti-interferon, MPI-0485520, at the 74th Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals, in Atlanta, Georgia.

10 Nov 2010

Research on AID enzyme could improve therapy for lymphoma, leukemia

A recent scientific discovery made by researchers at the Institut de recherches cliniques de Montr-al (IRCM) led by Dr. Javier Marcelo Di Noia, Director of the Mechanisms and Genetic Diversity research unit, was published online today by The Journal of Experimental Medicine. The team identified a mechanism regulating activation-induced deaminase (AID), which could be important for the therapy of some types of lymphoma and leukemia.

2 Nov 2010

AnaptysBio announces issuance of two new patents for SHM-XEL platform

AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, announced the issuance of patents in the US and Europe that provide additional coverage for its SHM-XEL platform. These patents extend AnaptysBio's leadership in the use of somatic hypermutation (SHM) for the discovery and optimization of antibodies and other proteins.

28 Oct 2010

Maven Semantic updates Lymphocyte Cell Biology research database

Maven Semantic announces updates to their Lymphocyte Cell Biology research database. The new database is now available to marketing, business development, competitor intelligence, KOL, medical affairs and related departments in the life sciences sector.

26 Oct 2010

BioCryst to present intravenous peramivir data for influenza treatment at IDSA meeting

BioCryst Pharmaceuticals, Inc. announced the presentation of data related to intravenous (i.v.) peramivir for the treatment of influenza at the 48th Annual Infectious Diseases Society of America (IDSA) meeting being held in Vancouver, Canada.

21 Oct 2010

Immune reaction to dystrophin may contribute to muscle disease: Study

An immune reaction to dystrophin, the muscle protein that is defective in patients with Duchenne muscular dystrophy, may pose a new challenge to strengthening muscles of patients with this disease, suggests a new study appearing in the October 7, 2010, issue of The New England Journal of Medicine.

7 Oct 2010

Tolerx presents otelixizumab preclinical research at 46th EASD

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the presentation of preclinical research describing the mechanism of action of otelixizumab at the 46th Annual Meeting of the European Association for the Study of Diabetes (EASD). In addition, Tolerx also announced that the first European patient was enrolled in DEFEND-2, a confirmatory Phase 3 clinical trial evaluating otelixizumab in autoimmune new-onset type 1 diabetes.

23 Sep 2010

Regular consumption of watercress can prevent breast cancer: Research

Watercress, the super food, is now watercress the breast cancer preventive according to a study released September 20, 2010 in The British Journal of Nutrition conducted by the Cancer Research Centre at the School of Medicine, Southampton General Hospital in the United Kingdom.

21 Sep 2010

Inovio Pharmaceuticals achieves promising results in VGX-3100 Phase I study

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has achieved best-in-class immune responses in its Phase I dose escalation study of VGX-3100, its DNA vaccine to treat pre-cancerous cervical dysplasias and cervical cancers caused by human papillomavirus (HPV) types 16 and 18.

13 Sep 2010

Researchers report massage improves body’s immune response

Researchers in Cedars-Sinai's Department of Psychiatry and Behavioral Neurosciences have reported people who undergo massage experience measureable changes in their body's immune and endocrine response.

9 Sep 2010

Scientists find epigenetic landscape map for tissue differentiation

Having charted the occurrence of a common chemical change that takes place while stem cells decide their fates and progress from precursor to progeny, a Johns Hopkins-led team of scientists has produced the first-ever epigenetic landscape map for tissue differentiation.The details of this collaborative study between Johns Hopkins, Stanford and Harvard appear August 15 in the early online publication of Nature.

17 Aug 2010